Denali Therapeutics submitted a Biologics License Application (BLA) for its therapy and the FDA granted Priority Review.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Denali Therapeutics submitted a Biologics License Application (BLA) for its therapy and the FDA granted Priority Review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Denali Therapeutics (United States)
company in South San Francisco, United States
Nothing else this week.
- FDA
Related events
- FDA accepts a BLA for biosimilar review and extends its review process to Health Canada.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Belite Bio, Inc. is seeking priority review for a drug application from the FDA and disclosed stock sales via SEC filing.
- FDA granted approval for the FAYUVI treatment on October 7, 2026.
Coverage
Newest first; wire copies grouped- Unknown outlet